Peptide Delivery Methods: Injectable vs. Oral vs. Sublingual vs. Nasal vs. Topical

Why Route of Administration Matters

For most drugs, the route of administration is a convenience or compliance question. For peptides, it’s a fundamental pharmacological question — because peptides face a challenge that small-molecule drugs don’t: they’re made of amino acids, and your digestive system is designed to break amino acids apart and absorb them as building blocks, not as intact signaling molecules.

The moment a peptide enters your gut, peptidases, proteases, and gastric acid begin cleaving it into its component amino acids. From the gut’s perspective, this is exactly what it’s supposed to do. From a therapeutic standpoint, it’s a significant bioavailability problem.

Different delivery routes either bypass or partially circumvent this problem — with different tradeoffs in bioavailability, onset, duration, practicality, and comfort.

Subcutaneous Injection: The Gold Standard

Why It Works Best

Subcutaneous (SubQ) injection deposits the peptide into the fatty tissue just below the skin, where it enters the interstitial fluid and then the bloodstream — bypassing gastric acid and digestive enzymes entirely.

Bioavailability for most peptides via SubQ: 70–100%

The peptide arrives largely intact, in a predictable concentration curve, at a predictable time. This is why virtually all published animal studies and human clinical trials use subcutaneous injection.

Practical Considerations

• Needle size: 29–31 gauge, 0.5 inch (for most SubQ peptides in abdominal fat)
• Injection sites: Abdomen (preferred), thigh, upper arm — rotate sites to avoid lipohypertrophy
• Reconstitution required: Lyophilized (freeze-dried) peptides must be reconstituted with bacteriostatic water before injection
• Storage: Most reconstituted peptides are stable for 28–30 days refrigerated; freeze-dried stable for months when kept cold and dry
• Sterile technique: Alcohol swab, new needle for each injection, never share needles

Best for: BPC-157, TB-500, GH secretagogues (CJC-1295, Ipamorelin, GHRP-2), GHK-Cu (systemic), Thymosin Alpha-1, Epitalon, PT-141

Intramuscular Injection (IM)

How It Differs from SubQ

Intramuscular injection places the peptide directly into muscle tissue, where vascularization is higher than subcutaneous fat. This produces faster absorption and higher peak concentrations vs. SubQ, but slightly shorter duration.

Bioavailability: Similar to SubQ (~80–100%), but faster onset

When It’s Used

IM injection is preferred for peptides where rapid peak concentration is clinically important, or when the injection volume is larger. Anabolic peptides, TB-500, and some GHRP protocols are sometimes administered IM.

Practical note: IM injection requires appropriate site knowledge (deltoid, vastus lateralis, gluteus medius) and carries slightly higher risk of injection site discomfort than SubQ.

Oral Administration

The Bioavailability Problem

Most peptides have essentially zero oral bioavailability through conventional swallowing — gastric acid and proteolytic enzymes destroy them before they can be absorbed intact. This is why insulin (a peptide hormone) cannot be taken as a pill and must be injected.

Exceptions and Workarounds

Orally designed peptides: Some peptides are specifically engineered for oral use. The most prominent example is semaglutide (Rybelsus) — which uses the SNAC technology (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) to temporarily increase gastric pH and enable absorption of intact semaglutide through the gastric mucosa. This is a pharmaceutical engineering achievement, not something achievable with standard peptides.

Small peptides: Very short peptides (2–3 amino acids) may survive gastric passage in some fraction. This is the theoretical basis for dipeptide supplements like carnosine.

BPC-157 oral controversy: Animal studies show oral BPC-157 has systemic effects despite theoretical degradation — suggesting either partial survival through gastric passage, absorption through gut-associated lymphoid tissue, or local effects in the gut that translate systemically via the gut-brain axis. This has not been studied in humans with validated pharmacokinetic methods.

Bioavailability: Essentially 0% for most peptides; variable and poorly characterized for some small/modified peptides; designed only in pharmaceutical-engineered products like Rybelsus

Intranasal (Nasal Spray)

Why the Nose Works

Nasal mucosa is highly vascularized and lacks the enzymatic hostile environment of the gut. Peptides absorbed through the nasal mucosa enter the bloodstream (and potentially the CNS via olfactory nerve pathways) without first-pass hepatic metabolism.

Bioavailability: Typically 10–40% for most peptides (highly variable by molecular size and formulation). Much lower than injection, but substantially higher than oral.

Which Peptides Use Intranasal Delivery

Clinically established:

• Oxytocin: Intranasal delivery is the standard research route; reaches brain via olfactory pathway
• Desmopressin (DDAVP): Intranasal form is FDA approved for diabetes insipidus and enuresis

Research community:

• Semax: Registered in Russia as intranasal; most human experience is intranasal
• Selank: Similarly used intranasally in Russian clinical practice
• DSIP: Intranasal protocols circulate in research communities
• PT-141: While approved SubQ, nasal formulations have been explored

Advantages: No injection; faster onset than oral; some CNS penetration for neuroactive peptides; more practical for daily use

Disadvantages: Lower and more variable bioavailability; nasal irritation with frequent use; less predictable systemic concentration

Sublingual (Under the Tongue)

The Mechanism

Sublingual absorption through the mucous membranes under the tongue bypasses first-pass hepatic metabolism and gastric destruction — similar logic to intranasal but with different mucosa characteristics.

Bioavailability: Generally low for larger peptides; better for smaller molecules

Current Use

Sublingual delivery for peptides is less established than intranasal. Some compounding pharmacies have produced sublingual preparations of oxytocin, BPC-157, and sermorelin. Evidence for bioavailability via sublingual route for most peptides is anecdotal.

Key limitation: Peptides absorbed sublingually must still survive exposure to salivary enzymes before absorption, though this is less aggressive than gastric proteolysis.

Topical (Skin / Transdermal)

What Works Topically

Skin is an effective barrier — intentionally. Most large peptides cannot penetrate the stratum corneum in significant quantities without specific formulation technologies.

Where topical is well-established:

• GHK-Cu: The copper peptide is a cosmetic staple. At 2–5% concentration in serums, it demonstrably improves wound healing, collagen production, and skin texture. This is one of the most evidence-supported topical peptide applications.
• Palmitoyl Pentapeptide-4 (Matrixyl): Another cosmetically established topical peptide; multiple RCTs confirm skin-tightening and wrinkle-reducing effects.
• Argireline (Acetyl Hexapeptide-3): Botox-mimetic topical; limited but positive RCT evidence.
• SYN-AKE: Snake venom-mimetic peptide; reduces muscle micro-contractions.

Where transdermal is limited: Larger peptides (BPC-157, TB-500, GH secretagogues) have molecular weights too large to passively penetrate skin. Liposomal or iontophoretic formulations may improve penetration marginally but are not well-validated for most research peptides.

Choosing the Right Route

General rule: The research data for most peptides is based on subcutaneous injection. When using alternate routes, you are deviating from the evidence base and operating with additional uncertainty about bioavailability and dose.

Reconstitution Basics

Most injectable peptides are sold lyophilized (freeze-dried powder) and must be reconstituted before use:

1. Bacteriostatic water (BAC water) — sterile water with 0.9% benzyl alcohol as a preservative. The standard diluent for most peptides. Maintains sterility of multi-use vials.
2. Sodium chloride solution (0.9%) — used for single-use preparations or when BAC water is unavailable.
3. Use the Reconstitution Calculator at /tools#reconstitution-guide to determine how much BAC water to add for your desired concentration.

Example: 5 mg BPC-157 vial + 2.5 mL BAC water = 2 mg/mL solution. A 250 mcg dose would be 0.125 mL = 12.5 units on a U-100 syringe.